Ongororo ichangoburwa yakabudiswa mumagazini Cellular uye Molecular Gastroenterology uye Hepatology yakaratidza kuti gene mutation inonzi ATRX inogona kutungamirira kune ngozi yekuwedzera kwepancreatitis uye pancreatic cancer muvakadzi. Ichi chidzidzo chinoratidza kuwanikwa kwekutanga kwepabonde-yakanangana nemagene njodzi njodzi yekenza yepancreatic.
The team used a preclinical model to examine the effect of ATRX mutations on the adult pancreas. They deleted the ATRX gene and then studied its effect on pancreatic cancer susceptibility. The team found that the deletion of the ATRX gene in women increased the susceptibility to pancreatitis-related pancreatic damage and accelerated the progression of pancreatic cancer. Mune varume, shanduko yeATRX haiwedzere njodzi yekukuvara kwepancreatic, uye ichinonotsa kufambira mberi kwekenza yepancreatic.
The team ‘s preclinical results were compared with human samples from the International Cancer Genome Alliance database, which includes whole-genome sequence analysis of 729 patients. Dare rekutsvagurudza rakaona kuti 19% yevarwere inotakura shanduko muhurefu hwerudzi rweATRX, kusanganisira asiri macoding matunhu, ayo makumi manomwe muzana ari echikadzi. Kunyangwe shanduko zhinji dzinoita sedzisingavhiringidze kuteedzana kweAPRX protein, shanduko yakafungidzirwa kukanganisa ATRX basa rinoitika zvakanyanya muvakadzi.
Lawson musayendisiti uye mushandi wepurofesa Dr. Chris Pin akati, "Gomarara repancreatic chirwere chinoparadza zvikuru chinowanzoonekwa chiri padanho repamusoro. Varwere kazhinji havapindure kune aripo marapirwo, uye avhareji yehupenyu hwevarwere iri mushure mekuongororwa Pasati pamwedzi mitanhatu. “Pancreatitis chirwere chinoratidzirwa nekuzvimba kwerwatata uye chimwe chezvinhu zvakakosha zvine njodzi mukugadzira gomarara repancreatic. Kunyangwe kumwe kutsvagurudza kuchidikanwa, vakadzi vane kurwara nepancreatitis vanogona rimwe zuva kuzivikanwa seboka rine njodzi, uye iyi geni mutation inofanirwa kuongororwa.
In a follow-up study, Dr. Pin will work with French researchers to study patient tumarara samples in a new preclinical model. Their goal is to better understand the mechanism of ATRX mutations as a gender-specific risk factor. In order to develop better diagnosis and treatment methods for women carrying this mutation.
